Business
OncoSec Medical Announces Uplisting to The NASDAQ Stock Market LLC
OncoSec Medical Announces Uplisting to The NASDAQ Stock Market LLC.
About this update from Oncosec Medical Incorporated
[{"type":"text","content":"\n\n\n\nOncoSec Medical Announces Uplisting to The NASDAQ Stock Market LLC\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncoSec Medical Announces Uplisting to The NASDAQ Stock Market LLC\nPR Newswire\nSAN DIEGO, May 27, 2015\n\n\n\nSAN DIEGO, May 27, 2015 /PRNewswire/ -- OncoSec Medical Inc. (\"OncoSec\") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the company has received approval to begin trading its common stock on The NASDAQ Stock Market LLC. OncoSec's common stock will begin trading on The NASDAQ Stock Market LLC at the opening of market hours on Friday, May 29.   \n\n\"Over the past year, our team has made significant headway to build a strong, cutting-edge, clinical stage biotech company. As we become a NASDAQ-listed company, we are now able to communicate our progress with a broader audience, raise the visibility of OncoSec's capabilities, and generate more value for our shareholders,\" said Punit Dhillon, President and CEO of OncoSec. \"We are now in a better position to continue to advance our intratumoral immunotherapy technologies with the goal of one day benefiting cancer patients everywhere.\" \n\nAbout OncoSec Medical Inc. OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indic...